<DOC>
	<DOCNO>NCT00069446</DOCNO>
	<brief_summary>This Phase I , double blind , randomize , placebo-controlled study enroll approximately 50 adult subject Type 1 Type 2 diabetes mellitus chronic , diabetic foot ulcer . The study conduct approximately 12 investigational site United States .</brief_summary>
	<brief_title>A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor ( Telbermin ) Induction Healing Chronic , Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Signed Informed Consent 1880 year old For female childbearing potential , use effective method contraception : abstinence ; surgical sterilization ; oral contraceptive ; barrier contraception either condom , sponge , diaphragm conjunction spermicidal gel ; intrauterine device ( IUD ) ; contraceptive hormone implant patch Type 1 2 diabetes mellitus Single , fullthickness ( i.e. , extend subcutaneous tissue beyond ) ulcer foot malleolus involve bone , tendon , ligament , muscle Chronic ulcer duration ≥ 4 week &lt; 6 month Ulcer area sharp debridement ≥ 1.0 cm^2 ≤ 4.0 cm^2 Anklebrachial index ( ABI ) ≥ 0.6 ≤ 1.2 study foot Glycosylated hemoglobin A1c ( HbA1c ) ≤ 12 % History neoplasia current neoplasia ( exception nonmelanoma skin cancer ) Proliferative diabetic retinopathy wet agerelated macular degeneration Active ulcer infection cellulitis ulcer Ulcers etiology relate diabetes ( e.g. , thermal , chemical , radiation insult ) Connective tissue disease Active osteomyelitis study foot Subjects ulcer relate incompletely heal amputation wound Subjects Charcot deformity study foot involve study ulcer Immunosuppressive treatment , include radiation therapy , noninhaled corticosteroid ( inhale corticosteroid ≤ 1000 ug daily dose acceptable ) , chemotherapy Pregnancy lactation Multiple ulcer study foot Renal failure ( serum creatinine &gt; 3.0 mg/dL ) Poor nutritional status ( albumin &lt; 3.0 g/dL ) Known hypersensitivity ingredient telbermin , placebo , vehicle , include excipients formulation telbermin placebo gel ( trehalose dihydrate , polysorbate 20 , succinic acetic acid , succinic acetic acid disodium , hexahydrate ) Known prior inability complete require study visit treatment period Use investigational drug therapy study foot within past month Previous use plateletderived growth factor study ulcer within past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diabetic</keyword>
	<keyword>Diabetic Foot Ulcer</keyword>
</DOC>